Last reviewed · How we verify
CTC detection
CTC detection is a diagnostic technology that identifies and isolates circulating tumor cells (CTCs) from patient blood samples to enable cancer monitoring and prognosis assessment.
CTC detection is a diagnostic technology that identifies and isolates circulating tumor cells (CTCs) from patient blood samples to enable cancer monitoring and prognosis assessment. Used for Cancer monitoring and prognosis assessment across multiple solid tumors, Treatment response evaluation in cancer patients.
At a glance
| Generic name | CTC detection |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Circulating tumor cells are cancer cells that have shed from primary tumors and circulate in the bloodstream. CTC detection uses specialized techniques (such as immunomagnetic enrichment or microfluidic isolation) to capture and enumerate these rare cells from blood, providing a liquid biopsy approach for cancer detection, monitoring treatment response, and assessing disease progression without requiring tissue biopsy.
Approved indications
- Cancer monitoring and prognosis assessment across multiple solid tumors
- Treatment response evaluation in cancer patients
Common side effects
Key clinical trials
- Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients (NA)
- Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
- Colonography Versus Colonoscopy in High Risk Patient (NA)
- EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
- Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer (PHASE2)
- Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. (NA)
- Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy
- Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |